Article Text

Download PDFPDF

Targeting of phosphatidylserine by monoclonal antibodies enhances activity of immune checkpoint inhibitors in breast tumors
  1. Jian Gong1,
  2. Van Nguyen1,
  3. Shen Yin1,
  4. Rich Archer1,
  5. Emely Nguyen1,
  6. Jeff Hutchins2 and
  7. Bruce Freimark1
  1. Aff1 grid.430202.7Peregrine Pharmaceuticals, Inc Tustin CA USA
  2. Aff2 grid.430202.7Department of Clinical AffairsPeregrine Pharmaceuticals Inc. Tustin CA USA

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts

Phosphatidylserine (PS) is a phospholipid normally residing in the inner leaflet of the plasma membrane and becomes exposed on tumor vascular endothelial cells (ECs) and tumor cells. PS exposure becomes enhanced in response to chemotherapy, irradiation, and oxidative stresses in the tumor microenvironment. PS exposure in tumors promotes an immunosuppressive microenvironment which includes the recruitment of myeloid derived suppressor cells (MDSCs), immature dendritic cells, and M2-like macrophages as well as the production of anti-inflammatory cytokines [1]. In the present study, we evaluated the effect of a PS-targeting and anti-PD-1 antibodies in EMT-6 breast tumor model in Balb/c mice. Combination therapy inhibited tumor growth greater than the single agent therapies. Tumor growth inhibition correlates with infiltration of immune cells in tumors and induction of adaptive immunity. The combination of these mechanisms promotes strong, localized, anti-tumor responses without the side-effects of systemic immune activation. Our data demonstrate that combination of antibodies that block PS in combination with antibodies that block PD-1 may be promising therapy for breast cancer.


  1. 1.